Trials / Completed
CompletedNCT00657254
Extension Program for Bay 43-9006
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nexavar (Sorafenib, BAY43-9006) | Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal. |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2008-04-14
- Last updated
- 2014-12-23
Locations
6 sites across 4 countries: United States, Belgium, Canada, Germany
Source: ClinicalTrials.gov record NCT00657254. Inclusion in this directory is not an endorsement.